---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-029125"
form_type: "8-K"
ticker: "IRMD"
cik: "0001325618"
company_name: "IRADIMED CORP"
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:15:20.943241+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Iradimed Q1 revenue $22.0M (+13% YoY), EPS $0.45; declares $0.20 dividend; reaffirms FY guidance

## Summary
- Q1 revenue $22.0M (+13% YoY); GAAP diluted EPS $0.45 (+22% YoY); non-GAAP EPS $0.49 (+17% YoY).
- Declares regular quarterly dividend $0.20/share, payable May 29, 2026 to holders of record May 15, 2026.
- Reaffirms FY 2026 guidance: revenue $91M-$96M; GAAP EPS $1.90-$2.05; non-GAAP EPS $2.06-$2.21.
- Launched next-gen 3870 MRI-compatible IV infusion pump; early orders strong; Q2 shipments expected.
- Operating cash flow $8.3M, up 93% YoY; gross margin improved to 77% from 76%.

## SEC filing metadata
- accession: 0001628280-26-029125
- form_type: 8-K
- ticker: IRMD
- cik: 0001325618
- company_name: IRADIMED CORP
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1325618/000162828026029125/0001628280-26-029125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1325618/000162828026029125/irmd-20260501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-029125
- JSON: https://secwatch.observer/filing/0001628280-26-029125.json
- Plain text: https://secwatch.observer/filing/0001628280-26-029125.txt

## Key facts
- Earnings Releases
  IRADIMED CORP reported first quarter of 2026 results: revenue revenue of $22.0 million, net income net income of $5.8 million, EPS $0.45 per diluted share. Guidance reaffirmed.
  - Period: first quarter of 2026
  - Revenue: revenue of $22.0 million
  - Net income: net income of $5.8 million
  - EPS: $0.45 per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: IRADIMED CORPORATION Reports First Quarter 2026 Financial Results Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance • Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025. • Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000162828026029125/0001628280-26-029125-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.